Relationship between tumor biomarkers and efficacy in EMILIA, a phase III study of trastuzumab emtansine in HER2-Positive metastatic breast cancer

Clinical Cancer Research

Volumn 22, Issue 15, 2016, Pages 3755-3763

  Baselga, José ^a   Phillips, Gail D Lewis ^b   Verma, Sunil ^c   Ro, Jungsil ^d   Huober, Jens ^e,h   Guardino, Alice E ^b   Samant, Meghna K ^b   Olsen, Steve ^b   De Haas, Sanne L ^f   Pegram, Mark D ^g  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b GENENTECH INC   (United States)

^c DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^d National Cancer Center   (South Korea)

^e CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

^g STANFORD CANCER INSTITUTE   (United States)

^h UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN HER3; PROTEIN PIK3CA; TRASTUZUMAB EMTANSINE; TUMOR MARKER; UNCLASSIFIED DRUG; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MAYTANSINE; PHOSPHATIDYLINOSITOL 3 KINASE; TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; EGFR GENE; FEMALE; GENE MUTATION; HER2 GENE; HER3 GENE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MARKER GENE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PIK3CA GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PTEN GENE; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT DURATION; ANALOGS AND DERIVATIVES; ANIMAL; BREAST TUMOR; CANCER STAGING; CLINICAL TRIAL; DISEASE MODEL; DRUG SCREENING; FOLLOW UP; KAPLAN MEIER METHOD; METABOLISM; METASTASIS; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RETREATMENT;

ANIMALS; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; BIOMARKERS, TUMOR; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MAYTANSINE; MICE; NEOPLASM METASTASIS; NEOPLASM STAGING; PHOSPHATIDYLINOSITOL 3-KINASES; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RETREATMENT; TRASTUZUMAB; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84980338826     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-2499     Document Type: Conference Paper

References (34)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235: 177-82.
2. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37.
3. Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor 2-positive breast cancer. J Clin Oncol 2009;27:5838-47.
4. Mariani G, Fasolo A, De Benedictis E, Gianni L. Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer. Nat Clin Pract Oncol 2009;6:93-104.
5. Del Mastro L, Lambertini M, Bighin C, Levaggi A, D'Alonzo A, Giraudi S, et al. Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients. Expert Rev Anticancer Ther 2012;12:1391-405.
6. Lee-Hoeflich ST, Crocker L, Yao E, PhamT, MunroeX, Hoeflich KP, et al. A central role for HER3 in HER2-amplified breast cancer: Implications for targeted therapy. Cancer Res 2008;68:5878-87.
7. Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012;487:505-9.
8. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6:117-27.
9. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007;12:395-402.
10. Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 2008;68:9221-30.
11. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001;93:1852-57.
12. Esteva FJ, Guo H, Zhang S, Santa-Maria C, Stone S, Lanchbury JS, et al. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 2010;177:1647-56.
13. Razis E, Bobos M, Kotoula V, Eleftheraki AG, Kalofonos HP, Pavlakis K, et al. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast Cancer Res Treat 2011;128:447-56.
14. Baselga J, Cortes J, Im SA, Clark E, Ross G, Kiermaier A, et al. Biomarker analyses in CLEOPATRA: A phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J Clin Oncol 2014;32:3753-61.
15. Majewski I, Nuciforo PG, Mittempergher L, Bosma AJ, Eidtmann H, Holmes E, et al. PI3KCA mutations are associated with decreased benefit to neoadjuvant HER2-targeted therapies in breast cancer. J Clin Oncol 2015;33:1334-39.
16. Park YH, Jung HA, Choi MK, Chang W, Choi YL, Do IG, et al. Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment. Br J Cancer 2014;110:384-91.
17. Loibl S, von Minckwitz G, Schneeweiss A, Paepke S, Lehmann A, Rezai M, et al. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (HER2) therapy in primary HER2-overexpressing breast cancer. J Clin Oncol 2014;32:3212-20.
18. Lee JW, Soung YH, Kim SY, Lee HW, Park WS, Nam SW, et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005;24:1477-80.
19. Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 2011;128:347-56.
20. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008;68:9280-90.
21. Erickson HK, Lewis Phillips GD, Leopold DD, Provenzano CA, Mai E, Johnson HA, et al. The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates. Mol Cancer Ther 2012;11:1133-42.
22. Burris HA III, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011;29:398-405.
23. Krop IE, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, et al. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol 2012;30:3234-41.
24. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783-91.
25. Krop IE, Kim S-B, González-Martín A, LoRusso PM, Ferrero JM, Smitt M, et al. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): A randomized, open-label, phase 3 trial. Lancet Oncol 2014;15:689-99.
26. Perez EA, Hurvitz SA, Amler LC, Mundt KE, Ng V, Guardino E, et al. Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: A randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer. Breast Cancer Res 2014;16:R50.
27. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, et al. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Oncol 2005;2:416-22.
28. Miller KD, Diéras V, Harbeck N, Andre F, Mahtani RL, Gianni L, et al. Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer. J Clin Oncol 2014;32:1437-44.
29. Gymnopolous M, Elsliger MA, Vogt PK. Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci U S A 2007; 104:5569-74.
30. Kim SB, Wildiers H, Krop IE, Leung ACF, Trudeau C, Yu R, et al. Relationship between tumor biomarkers and efficacy in TH3RESA, a phase 3 study of trastuzumab emtansine (T-DM1) vs treatment of physician's choice in HER2-positive advanced breast cancer previously treated with trastuzumab and lapatinib. J Clin Oncol 32:5s, 2014 (suppl; abstr 605).
31. Hurvitz SA, Andre F, Jiang Z, Shao Z, Mano MS, Neciosup SP, et al. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLE-RO-1): a phase 3, randomised, double-blind, multicentre trial. Lancet Oncol 2015;16:816-29.
32. André F, O'Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 2014;15:580-91.
33. Slamon DJ, Hurvitz SA, Chen D, Andre F, Tseng L-M, Maria Jerusalem GH, et al. Predictive biomarkers of everolimus efficacy in HER2+ advanced breast cancer: Combined exploratory analysis from BOLERO-1 and BOLE-RO-3. J Clin Oncol 33, 2015 (suppl; abstr 512).
34. Fabi A, Di Benedetto A, Metro G, Perracchio L, Nisticò C, Di Filippo F, et al. HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care. Clin Cancer Res 2011;17: 2055-64.